Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Significant Decline in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report) saw a large decline in short interest in May. As of May 15th, there was short interest totalling 155,600 shares, a decline of 38.1% from the April 30th total of 251,400 shares. Based on an average trading volume of 92,600 shares, the days-to-cover ratio is presently 1.7 days. Approximately 2.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On Senti Biosciences

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Senti Biosciences in the 4th quarter worth about $47,000. Renaissance Technologies LLC acquired a new position in shares of Senti Biosciences during the fourth quarter valued at $181,000. Heights Capital Management Inc. acquired a new position in shares of Senti Biosciences during the first quarter valued at $2,520,000. Finally, Nantahala Capital Management LLC acquired a new position in Senti Biosciences in the first quarter valued at about $2,984,000. 25.73% of the stock is owned by hedge funds and other institutional investors.

Senti Biosciences Stock Performance

Senti Biosciences stock traded up $0.06 during midday trading on Tuesday, reaching $3.15. The company's stock had a trading volume of 20,443 shares, compared to its average volume of 799,687. The firm has a market capitalization of $82.16 million, a PE ratio of -0.20 and a beta of 2.31. Senti Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $16.94. The stock's 50 day simple moving average is $3.38 and its 200 day simple moving average is $3.80.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.85). The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $1.30 million. Equities analysts predict that Senti Biosciences will post -14.54 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Chardan Capital reaffirmed a "buy" rating and issued a $12.00 target price on shares of Senti Biosciences in a research report on Friday, May 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.